Abstract
Gynecological diseases-encompassing polycystic ovary syndrome, endometriosis, infertility, and malignancies-represent a significant global health burden affecting women's quality of life, reproductive capacity, and long-term health outcomes. While traditional diagnostics rely on protein-based biomarkers, clinical phenotyping, and imaging, these approaches often lack the sensitivity and specificity required for early detection and personalized intervention. Glycomics, the comprehensive study of carbohydrate structures on proteins and lipids, represents an emerging molecular frontier in gynecological disease characterization and therapeutics. This review synthesizes current knowledge regarding glycomic dysregulation across gynecological conditions, elucidates how aberrant glycosylation patterns serve as disease-specific biomarkers, and demonstrates key translational applications, such as glycoform-specific CA-125. By integrating glycomics with complementary omics technologies and artificial intelligence-driven analysis, a transformative diagnostic paradigm is emerging that promises earlier detection, improved risk stratification, and precision-guided therapeutics for women with gynecological disorders.